Just in the past April, the pharmaceutical and biological industry was broken the threshold of brokerage institutions, Wind data show that last month, brokerages conducted research on 94 enterprises in the pharmaceutical and biological industry. Among them, the number of pharmaceutical stocks such as East China Medicine, Open Medical, and Huaxia Ophthalmology that have been investigated is more than 400.

From the perspective of the content of institutional research, most of them focus on the outlook of the surveyed company's business situation in 2023, the business situation of the surveyed company in the first quarter of 2023, and the impact of collection on the surveyed company.

For example, East China Pharmaceutical, which has been surveyed by more than 400 institutions, forecast the growth of the company's pharmaceutical industry and medical beauty business this year. In the medical beauty business, Sinclair expects that the growth rate of overseas medical beauty will gradually pick up from the second quarter. In terms of domestic medical beauty, as the domestic consumer market continues to recover and improve, the domestic medical beauty business is also expected to achieve better performance this year. In the pharmaceutical industry, the company's core products are in the growth stage.

When accepting institutional research, Open Medical replied: "In the past two years, the growth of the company's main ultrasound and endoscopy product lines has been in line with the development plan formulated by the company, and the goal of stable growth of ultrasound business and rapid growth of endoscopy business has been successfully achieved." Looking forward to 2023, with the product advantages accumulated by the company's high proportion of R&D investment for many years, as well as the steady growth of domestic and foreign medical equipment markets, and the support of relevant domestic policies, the company is still confident in 2023 to achieve the stable growth of ultrasound business and rapid growth of endoscopy business goals."

Huaxia Ophthalmology is also optimistic in the process of institutional research, the company said that since 2023, in addition to January, the company's business indicators have been restored to the fast track since February, and the management is full of confidence in the company's future growth. In the next five years, Huaxia Ophthalmology will anchor an annual performance growth target of more than 30%.

It is worth mentioning that the ophthalmic track where Huaxia Ophthalmology is located has soared recently, and the analysis believes that this is influenced by the performance of the ophthalmic medical sector in the first quarter, on the other hand, a number of ophthalmic medical companies have gained institutional positions in the first quarter. For example, Gulen took the lead in increasing the holdings of eye care companies, including Huaxia Eye and Purui Eye, further heating up the sector.

In the first quarter of 2023, Huaxia Ophthalmology achieved operating income of 931 million yuan, an increase of 15.10%; Net profit attributable to shareholders of listed companies amounted to RMB150 million, up 34.01% year on year. In addition to its good performance, Gulen's China-Europe healthcare mix added 953,800 shares of Huaxia Ophthalmology in the first quarter of 2023, accounting for about 1.07% of the total share capital.

In addition to Huaxia Ophthalmology, the eye care stock Puri Ophthalmology, which was also awarded the Grantham position in April, has also been investigated by more than 100 institutions, including the Central Europe Fund, Penghua Fund, Harvest Fund, BlackRock Fund and many other institutions in the list. In the survey, Puri Eye mentioned that the company will open five new ophthalmic specialty hospitals in 2022, and the investment of these hospitals will contribute to the growth of the first quarter, and the company will still maintain a moderate expansion in accordance with the investment plan this year.

Analysts from Deppon Securities believe that the pharmaceutical and biological industry is expected to usher in a "Davis double tap" in 2023, and the two major supports from performance and policy will make the industry usher in a structured market.

For the main line of pharmaceutical and biological investment, Southwest Securities said that it continues to be optimistic about three main lines, namely, innovative drugs, the core line of pharmaceutical recovery after the epidemic, autonomous control and industrial chain security.

Disclaimer: In no event does the information or opinions expressed herein constitute investment advice to anyone.

Source: Pharmaceutical Network